Evidence map›Paper›PMID 29903741›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2018

Eric C Yang, Richard A Schwarz, Alexander K Lang, Nancy Bass, Hawraa Badaoui, Imran S Vohra, Katelin D Cherry, Michelle D Williams, Ann M Gillenwater, Nadarajah Vigneswaran and 1 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Eric C YangDepartment of Bioengineering, Rice University, Houston, Texas.
Richard A SchwarzDepartment of Bioengineering, Rice University, Houston, Texas.
Alexander K LangThe University of Texas School of Dentistry at Houston, Houston, Texas.
Nancy BassThe University of Texas School of Dentistry at Houston, Houston, Texas.
Hawraa BadaouiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Imran S VohraDepartment of Bioengineering, Rice University, Houston, Texas.
Katelin D CherryDepartment of Bioengineering, Rice University, Houston, Texas.
Michelle D WilliamsDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ann M GillenwaterDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nadarajah VigneswaranThe University of Texas School of Dentistry at Houston, Houston, Texas.
Rebecca R Richards-KortumDepartment of Bioengineering, Rice University, Houston, Texas. rkortum@rice.edu.
Rice University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Houston · USBaylor College of Medicine · US

Funding

Optical Systems for In Vivo Molecular Imaging of CancerR01CA103830 · NCI · UNIVERSITY OF TEXAS AUSTIN · PI RICHARDS-KORTUM, REBECCA R. · 2004 to 2015
$12.4M
(PQC2) Optical Hallmarks of Aggressive Clones Within Oral Field CancerizationR01CA185207 · NCI · RICE UNIVERSITY · PI GILLENWATER, ANN M, RICHARDS-KORTUM, REBECCA R. · 2014 to 2017
$2.6M
Aptamer mediated targeting of Fanconi Anemia oral cancer initiating cellsR01DE024392 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ANNAPRAGADA, ANANTH V, VIGNESWARAN, NADARAJAH · 2014 to 2017
$1.5M
An Automated, Optical Imaging Platform for Early Detection of Oral NeoplasiaF30CA213922 · NCI · RICE UNIVERSITY · PI YANG, ERIC · 2017 to 2018
$96k
NCI NIH HHS F30 CA213922NCI NIH HHS R01 CA103830NCI NIH HHS R01 CA185207NIDCR NIH HHS R01 DE024392
6 · The paper itself

Abstract

Early detection of oral cancer and oral premalignant lesions (OPL) containing dysplasia could improve oral cancer outcomes. However, general dental practitioners have difficulty distinguishing dysplastic OPLs from confounder oral mucosal lesions in low-risk populations. We evaluated the ability of two optical imaging technologies, autofluorescence imaging (AFI) and high-resolution microendoscopy (HRME), to diagnose moderate dysplasia or worse (ModDys

Indexed as

AdultDental Impression TechniqueDisease ProgressionEarly Detection of CancerEndoscopyFeasibility StudiesHumansImage Processing, Computer-AssistedMouth MucosaMouth NeoplasmsMultimodal ImagingOptical ImagingPrecancerous ConditionsROC CurveYoung Adult

Identifiers

PMID29903741
PMCPMC6082417
OpenAlexW2808553051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.